SLC12A2 and acute respiratory distress syndrome: Despite an approval of the conservative fluid management strategy, recent guidelines on COVID 19 induced ARDS management (Alhazzani et al., 2020; Matthay et al., 2020) do not mention furosemide or other NKCC1 inhibitors like bumetanide.